Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
September 24 2017 - 8:00AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, announced today its
observance of The FH Foundation’s annual Familial
Hypercholesterolemia (FH) Awareness Day.
Chief Executive Officer Mary Szela said, "On FH
Awareness Day, we are proud to stand with The FH Foundation and
support their mission of increasing awareness of FH, including
homozygous FH (HoFH), a very serious and often undiagnosed disease.
Education and awareness help to support early diagnosis and
treatment, and ultimately make an impact for individuals and
families who are impacted by this disease.”
FH is a genetic condition that impacts the
body’s ability to remove cholesterol that the body naturally
produces. As a result, blood cholesterol levels are significantly
elevated. There are two forms of the disease: heterozygous FH
(HeFH), in which the genetic defect causing the impairment is
inherited from one parent; and HoFH, in which the genetic defect is
inherited from both parents. HoFH is the most severe form of the
disorder.
Established in 2012, FH Awareness Day is a
campaign initiated by the FH Foundation to raise awareness of FH in
the general public. This annual event is held during National
Cholesterol Education Month.
To learn more about familial
hypercholesterolemia, visit www.thefhfoundation.org.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to
developing new standards of care for individuals living with rare
diseases. Novelion has a diversified commercial portfolio through
its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which
includes MYALEPT® and JUXTAPID®, and is also developing zuretinol
acetate for the potential treatment of inherited retinal disease
caused by underlying mutations in RPE65 or LRAT genes. The
company seeks to advance its portfolio of rare disease therapies by
investing in science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate
CommunicationsNovelion
Therapeutics857-242-5024amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Sep 2023 to Sep 2024